What is the Return on Assets (ROA) of Xilio Therapeutics this year?
The Return on Assets (ROA) of Xilio Therapeutics is -1.25 undefined this year.
In 2024, Xilio Therapeutics's return on assets (ROA) was -1.25, a 97.87% increase from the -0.63 ROA in the previous year.
Xilio Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Comparing Xilio Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Investors consider Xilio Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Variations in Xilio Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
The Return on Assets (ROA) of Xilio Therapeutics is -1.25 undefined this year.
The ROA of Xilio Therapeutics has increased by 97.87% compared to the previous year.
A high ROA is advantageous for investors of Xilio Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.
A low ROA can be unfavorable for investors of Xilio Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
An increase in ROA of Xilio Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.
A reduction in the ROA of Xilio Therapeutics can be an indicator of lower asset efficiency and profitability.
Some factors that can influence the ROA of Xilio Therapeutics include revenue, operating costs, asset structure, and industry average.
The ROA of Xilio Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
To improve ROA, Xilio Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
Over the past 12 months, Xilio Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xilio Therapeutics is expected to pay a dividend of 0 USD.
The current dividend yield of Xilio Therapeutics is .
Xilio Therapeutics pays a quarterly dividend. This is distributed in the months of .
Xilio Therapeutics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Xilio Therapeutics is assigned to the 'Health' sector.
To receive the latest dividend of Xilio Therapeutics from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.
The last dividend was paid out on 9/9/2024.
In the year 2023, Xilio Therapeutics distributed 0 USD as dividends.
The dividends of Xilio Therapeutics are distributed in USD.
Our stock analysis for Xilio Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xilio Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.